Trials / Completed
CompletedNCT06609161
A Study to Compare Oral Formulations of Tedizolid Phosphate in Healthy Adults (MK-1986-044)
A Study to Evaluate the Definitive Bioequivalence of Tedizolid Phosphate Single-Unit-Dose Sachet Powder for Oral Suspension Compared to Tedizolid Phosphate Powder for Oral Suspension Bottle Used in Pediatric Clinical Studies
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 18 (actual)
- Sponsor
- Merck Sharp & Dohme LLC · Industry
- Sex
- All
- Age
- 19 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
The goal of the study is to learn what happens to different oral formulations of tedizolid phosphate (MK-1986) in a healthy person's body over time. Researchers want to know if there is a difference in the oral formulations absorption and elimination from the healthy persons body.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tedizolid Phosphate Oral Formulation 1 (Reference) | Formulation 1 (FM1) powder for oral suspension. |
| DRUG | Tedizolid Phosphate Oral Formulation 2 (Test) | Formulation 2 (FM2) powder for oral suspension. |
Timeline
- Start date
- 2024-07-16
- Primary completion
- 2024-08-08
- Completion
- 2024-08-08
- First posted
- 2024-09-24
- Last updated
- 2024-09-27
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06609161. Inclusion in this directory is not an endorsement.